Numerate’s Drug Design Platform Scales to 10,000+ Cores Using Spot Instances
7/10/2012 10:16:21 AM
SAN BRUNO, Calif.--(BUSINESS WIRE)--Numerate, Inc., a technology platform company that is leveraging proprietary algorithms and the power of cloud computing to transform the drug design process, announced today that its drug discovery platform, based on its open-source distributed framework, Numatix, has been shown to reliably and cost-effectively scale to 10,000+ cores using spot instances on Amazon Web Services’ Elastic Cloud Compute (AWS EC2). The 10,000+ cores were used to screen virtual compounds against predictive assay models in one of the company’s commercial partnerships.
comments powered by